Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

24 Mar 2014

Abstract excerpt

BACKGROUND: While the treatment of HER2 over-expressing breast cancer with recent HER-targeted drugs has been highly effective for some patients, primary (also known as innate) or acquired resistance limits the success of these drugs. microRNAs have potential as diagnostic, prognostic and predictive biomarkers, as well as replacement therapies. Here we investigated the role of microRNA-630 (miR-630) in breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circular RNAs in diseases
Share to HER2/EGFR in Cancer Research
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24655723
DOI: 10.1186/1476-4598-13-71

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerPMID 24655723Read ↗

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancerSemantic proximity Read ↗

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.Semantic proximity Read ↗

A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted TherapySemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

Coordinated regulation of WNT/β-catenin, c-Met, and Integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traitsSemantic proximity Read ↗

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapySemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.